Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the results from etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC) presented at ASCO 2024

Ticker(s): RCUS

Who's the expert?

Institution: Hospital Fundacion Jimenez Diaz, Madrid (START Madrid)

Director of Clinical Research at the Phase 1 Trials Unit START Madrid-FJD.
Treats over 250 patients per year with solid tumors.
Primary investigator on more than 30 phase 1 clinical trials in Medical oncology, Neuro-Oncology and Gastrointestinal Tumors; Research expertise in early clinical trials and drug development with special focus on targeted therapies, cancer immunotherapy and adoptive cell therapy.

Interview Goal

On this call we will be discussing the potential of Arcus’ Etrumadenant combined with zimberelimab (Z) (anti-PD-1 antibody), and FOLFOX/bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC).

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.